Free Trial

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Ironwood Pharmaceuticals logo
$1.27 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.24 -0.03 (-2.76%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Key Stats

Today's Range
$1.23
$1.28
50-Day Range
$0.67
$1.27
52-Week Range
$0.53
$5.21
Volume
786,859 shs
Average Volume
1.63 million shs
Market Capitalization
$206.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.94
Consensus Rating
Hold

Company Overview

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

IRWD MarketRank™: 

Ironwood Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 168th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ironwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ironwood Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Ironwood Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ironwood Pharmaceuticals are expected to grow by 150.00% in the coming year, from $0.10 to $0.25 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ironwood Pharmaceuticals is 31.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ironwood Pharmaceuticals is 31.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.38.

  • Read more about Ironwood Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.45% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 17.61%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ironwood Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ironwood Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.45% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 17.61%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ironwood Pharmaceuticals has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.70% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Ironwood Pharmaceuticals' insider trading history.
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRWD Stock News Headlines

Ironwood (IRWD) Q2 EPS Jumps 600%
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.tc pixel
See More Headlines

IRWD Stock Analysis - Frequently Asked Questions

Ironwood Pharmaceuticals' stock was trading at $4.43 at the beginning of 2025. Since then, IRWD shares have decreased by 71.3% and is now trading at $1.27.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. The biotechnology company had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 2.46% and a negative net margin of 2.25%.

Top institutional investors of Ironwood Pharmaceuticals include Armistice Capital LLC (9.98%), Acadian Asset Management LLC (4.05%), AQR Capital Management LLC (3.81%) and Marshall Wace LLP (2.47%). Insiders that own company stock include Thomas A Mccourt, Michael Shetzline, Jason Rickard, Sravan Kumar Emany, Andrew Davis, Minardo John, Ronald Silver, Julie Mchugh, Jon R Duane and Catherine Moukheibir.
View institutional ownership trends
.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/07/2025
Today
8/26/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRWD
CIK
1446847
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$0.70
Potential Upside/Downside
+293.6%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
12.55
P/E Growth
N/A
Net Income
$880 thousand
Net Margins
-2.25%
Pretax Margin
13.91%
Return on Equity
-2.46%
Return on Assets
2.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.82
Quick Ratio
0.82

Sales & Book Value

Annual Sales
$351.41 million
Price / Sales
0.58
Cash Flow
$0.05 per share
Price / Cash Flow
25.68
Book Value
($1.88) per share
Price / Book
-0.67

Miscellaneous

Outstanding Shares
162,430,000
Free Float
141,805,000
Market Cap
$203.85 million
Optionable
Optionable
Beta
0.33

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IRWD) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners